Friday, July 10, 2026

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Clinical program

Carfilzomib

Phase 1 · small molecule · Acute Lymphoblastic Leukemia (ALL)

Carfilzomib for Acute Lymphoblastic Leukemia (ALL) is a Phase 1 program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Internal code CFZ008

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lxo Ireland Designated Activity Company
Phase
Phase 1
Modality
small_molecule
Indication
Acute Lymphoblastic Leukemia (ALL)
Status
completed
Trials
1